. Author manuscript; available in PMC: 2020 Apr 23.

Published in final edited form as: Biochim Biophys Acta Rev Cancer. 2018 Dec 30;1871(1):138–159. doi: 10.1016/j.bbcan.2018.11.007

Table 8.

Major CRL4s targeted therapies

Drug	Mechanism	Function	Preclinical evidence	Clinical trial	FDA approval
E7820	Promoting DCAF15-CAPERα degradation	Anti-growth in colorectal cancer cells²⁴⁷	Yes	Completed	Not yet
CQS	Promoting DCAF15-CAPERα degradation	Anti-growth in colorectal cancer cells²⁴⁷	Yes	Completed	Not yet
Indisulam	Promoting DCAF15-CAPERα degradation	Anti-growth in colorectal cancer cells^173,247	Yes	Completed	Not yet
CC-220	Promoting CRBN- IKZF1 and IKZF3 degradation	Anti-tumor effect against multiple myeloma cells³³¹	Yes	Ongoing	Not yet
Lenalidomide	Promoting CRBN- CK1α degradation	Anti-tumor effect against myelodysplastic syndrome¹⁶⁴	Yes	Completed	Approved
Lenalidomide	Promoting CRBN- IKZF1 and IKZF3 degradation	Anti-tumor effect against multiple myeloma cells^162,208,209	Yes	Completed	Approved
Thalidomide	Promoting CRBN- IKZF1 and IKZF3 degradation	Anti-tumor effect against multiple myeloma cells²⁴⁸	Yes	Completed	Approved
Pomalidomide	Promoting CRBN- IKZF1 and IKZF3 degradation	Anti-tumor effect against multiple myeloma cells²⁴⁸	Yes	Completed	Approved
CC-885	Promoting CRBN- GSPT1 degradation	Anti-tumor effect against leukemic cells¹⁶³	Yes	Not yet	Not yet
Pevonedistat	Inactivation of DCAF2-SET8/p21 degradation	Anti-tumor effect against melanoma cells¹⁵⁰	Yes	Completed	Not yet

Abbreviations: CQS: chloroquinoxaline sulfonamide; CC-220: alias Compound 6.